Aclaris Therapeutics Inc (ACRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Aclaris Therapeutics Inc (ACRS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH436744D
  • |
  • Pages: 72
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Aclaris Therapeutics Inc (Aclaris Therapeutics) is a dermatologist-led bio-pharmaceutical company which focuses on identifying, developing, and commercializing prescription drug products for unmet needs in aesthetic and medical dermatology as well as immunology. Its lead product, ESKATA, is a proprietary formulation of high-concentration hydrogen peroxide topical solution prescribed for the treatment of raised seborrheic keratosis (SK). The company's pipeline products include A-101, ATI-502, ATI-501, ATI-450-MK-2 inhibitor, soft JAK inhibitor, ITK oral anti-IL17 and ITK topical anti-IL17. Aclaris Therapeutics' pipeline products are used for the treatment of common warts, alopecia areata, androgenetic alopecia, psoriasis, arthritis, gangrenosum, inflammatory skin diseases, atopic dermatitis and others. The company also develops investigational drugs to treat skin and hair conditions. Aclaris Therapeutics is headquartered in Wayne, Pennsylvania, the US.

Aclaris Therapeutics Inc (ACRS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13

Venture Financing 14

Confluence Life Sciences Raises USD4.8 Million in Financing 14

Aclaris Therapeutics Raises USD40 Million in Series C Financing 15

Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17

Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18

Confluence Life Sciences Raises Funds Through Venture Financing 19

Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20

Aclaris Therapeutics Raises USD 21 Million In Series A Financing 21

Confluence Life Sciences Raises USD 4 Million In Series A Financing 23

Partnerships 24

Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24

Licensing Agreements 25

Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25

Vixen Pharma Enters into Licensing Agreement with Columbia University 26

Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27

Equity Offering 28

Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28

Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30

Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32

Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33

Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35

Aclaris Therapeutics Raises USD63.3 Million in IPO 36

Acquisition 38

Aclaris Therapeutics Acquires Confluence Life Sciences 38

Aclaris Therapeutics to Acquire Vixen Pharma 39

Aclaris Therapeutics Inc-Key Competitors 40

Aclaris Therapeutics Inc-Key Employees 41

Aclaris Therapeutics Inc-Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Financial Announcements 43

Aug 03, 2018: Aclaris Therapeutics reports second quarter 2018 financial results and provides update on clinical and commercial developments 43

May 08, 2018: Aclaris Therapeutics Reports First Quarter 2018 Financial Results and Provides Update on Clinical and Commercial Developments 46

Mar 12, 2018: Aclaris Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 49

Nov 07, 2017: Aclaris Therapeutics Reports Third Quarter 2017 Financial Results 53

Aug 08, 2017: Aclaris Therapeutics Reports Second Quarter 2017 Financial Results 57

May 09, 2017: Aclaris Therapeutics Reports First Quarter 2017 Financial Results 59

Mar 15, 2017: Aclaris Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 61

Corporate Communications 63

Jun 15, 2018: Aclaris Therapeutics Appoints Dr. David Gordon As Chief Medical Officer 63

Apr 24, 2018: Aclaris Therapeutics Announces Names Bryan Reasons As Director And Chairman Of Audit Committee 64

Aug 09, 2017: Aclaris Announces Appointment of Andrew Schiff to Board of Directors 65

Jan 26, 2017: Aclaris Therapeutics Announces Appointment of Andrew Powell to Board of Directors 66

Product News 67

05/15/2018: Aclaris Therapeutics to Support Symposium on JAK Inhibitors at the International Investigative Dermatology 2018 Meeting 67

04/24/2017: Aclaris Therapeutics Hosts Symposium on JAK Inhibitors at the 76th Annual Society for Investigative Dermatology Meeting 68

Product Approvals 69

Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 69

Clinical Trials 70

Dec 19, 2017: Aclaris Therapeutics Initiates a Pilot Clinical Trial to Study ATI-50002 Topical in Patients with Vitiligo 70

May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72

List of Figures

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aclaris Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aclaris Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Aclaris Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Aclaris Therapeutics to Acquire Worldwide Rights of RHOFADE from Allergan Sales 13

Confluence Life Sciences Raises USD4.8 Million in Financing 14

Aclaris Therapeutics Raises USD40 Million in Series C Financing 15

Confluence Life Sciences Raises USD2.4 Million in Post Seed Financing Round 17

Aclaris Therapeutics Raises USD21 Million in Series B Venture Financing 18

Confluence Life Sciences Raises Funds Through Venture Financing 19

Confluence Life Sciences Secures USD0.5 Million in Series A Funding Round 20

Aclaris Therapeutics Raises USD 21 Million In Series A Financing 21

Confluence Life Sciences Raises USD 4 Million In Series A Financing 23

Aclaris Therapeutics Enters Into Licensing Agreement with JAKPharm and Key Organics 24

Cipher Pharma Enters into Licensing Agreement with Aclaris Therapeutics 25

Vixen Pharma Enters into Licensing Agreement with Columbia University 26

Aclaris Therapeutics International Enters into Licensing Agreement with Rigel Pharma 27

Aclaris Therapeutics Raises USD106.9 Million in Public Offering of Shares 28

Aclaris Therapeutics Raises USD86.3 Million in Public Offering of Shares 30

Aclaris Therapeutics Raises USD20 Million in Public Offering of Shares 32

Aclaris Therapeutics Raises USD104.7 Million in Public Offering of Shares 33

Aclaris Therapeutics Raises USD20 Million in Private Placement of Shares 35

Aclaris Therapeutics Raises USD63.3 Million in IPO 36

Aclaris Therapeutics Acquires Confluence Life Sciences 38

Aclaris Therapeutics to Acquire Vixen Pharma 39

Aclaris Therapeutics Inc, Key Competitors 40

Aclaris Therapeutics Inc, Key Employees 41

Aclaris Therapeutics Inc, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Aclaris Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17745
Site License
USD 500 INR 35490
Corporate User License
USD 750 INR 53235

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com